Amgen, Inc. vs Sezzle Inc — how do they compare? Amgen, Inc. trades at $418.27 (market cap $225.15B), while Sezzle Inc trades at $131.49 (market cap $4.22B). The key difference: Amgen, Inc. is far larger — about 53.4× Sezzle Inc's market cap, and Amgen, Inc. pays a 2.42% dividend while Sezzle Inc pays none. Which is the better fit depends on your goals.
| AMGN | SEZL | |
|---|---|---|
Market Cap | $225.15B | $4.22B |
Sector | Health | Technology |
52-Week High | $417.20 | $188.55 |
52-Week Low | $271.18 | $50.97 |
Enterprise Value | $268.47B | $4.27B |
Dividend Yield | 2.42% | — |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →